Washington, D.C. 20549






Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) July 27, 2021



(Exact name of registrant as specified in its charter)







(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


100 – 740 McCurdy Road, Kelowna, BC Canada


V1X 2P7

(Address of principal executive offices)


(Zip Code)


Registrant’s telephone number, including area code (250) 765-6424



(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class




Name of each exchange on which registered

Common Stock, par value $0.001 per share

Warrants to Purchase Common Stock





The Nasdaq Capital Market

The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 8.01

Other Events


On July 27, 2021, Lexaria Bioscience Corp. (“Lexaria”) announced the additional expansion of its intellectual property portfolio with the allowance of its second patent in Japan. The patent is titled “Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof” and becomes the 21st patent granted to Lexaria and the 17th patent granted in Lexaria’s first patent family.


On July 28, 2021 Lexaria announced that its DehydraTECHTM technology was now incorporated into consumer brands available for sale in over 7,000 stores across the US, including Albertsons, Vons, Hudson News and Safeway.


On July 29, 2021 Lexaria issued partial results from human clinical study HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol  for potential application against hypertension. See Exhibit 99.1.


Item 9.01

Financial Statements and Exhibits



Press Release dated July 29, 2021



- 2 -





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





/s/ Chris Bunka

Chris Bunka

CEO, Principal Executive Officer


Date: July 30, 2021




- 3 -


Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Lexaria Bioscience Charts.
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Lexaria Bioscience Charts.